Beam Lilly will now own optin rights to jointly develop and commercialize with Verve gene editing medicines for heart disease that are aimed at several wellknown drug targets. The new deal brings the companies closer and allows Lilly to closely track Verves progress on programs aimed at other genes important to heart disease risk